Liraglutide enhances bone regeneration in a critical-size calvarial defect model in male rats: A comparative study with autogenous grafts, allografts, and xenografts.

Zavrak N, Lektemur Alpan A, Özmen Ö

Archives of oral biology15 Jan 2026

PMID41579495DOI10.1016/j.archoralbio.2026.106519PepBankPUB-41579495

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In rats with critical-size calvarial defects, graft combinations containing liraglutide had greater new bone formation.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide had greater new bone formation.
Peptide
Liraglutide
Outcome
IncreaseNew bone formation
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Histomorphometric data demonstrated that Liraglutide significantly enhanced the osteogenic performance of the grafts, resulting in greater new bone formation and defect closure (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949501
02AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In rats with critical-size calvarial defects, graft combinations containing liraglutide had greater defect closure.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide had greater defect closure.
Peptide
Liraglutide
Outcome
IncreaseDefect closure
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Histomorphometric data demonstrated that Liraglutide significantly enhanced the osteogenic performance of the grafts, resulting in greater new bone formation and defect closure (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949502
03AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Mechanism
In rats with critical-size calvarial defects, graft combinations containing liraglutide showed greater osteoblastic activity.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide showed greater bone-forming cell activity.
Peptide
Liraglutide
Outcome
IncreaseOsteoblastic activity
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Immunohistochemical results revealed that Liraglutide promoted osteoblastic activity while suppressing osteoclastic activity.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949503
04AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Mechanism
In rats with critical-size calvarial defects, graft combinations containing liraglutide showed lower osteoclastic activity.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide showed lower bone-resorbing cell activity.
Peptide
Liraglutide
Outcome
DecreaseOsteoclastic activity
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Immunohistochemical results revealed that Liraglutide promoted osteoblastic activity while suppressing osteoclastic activity.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949504
05AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In rats with critical-size calvarial defects, graft combinations containing liraglutide showed improved bone volume on micro-CT.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide showed improved bone volume.
Peptide
Liraglutide
Outcome
IncreaseBone volume
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Micro-CT findings supported these outcomes, indicating significant improvements in bone volume, trabecular thickness, and structural integrity.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949505
06AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In rats with critical-size calvarial defects, graft combinations containing liraglutide showed improved trabecular thickness on micro-CT.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide showed improved trabecular thickness.
Peptide
Liraglutide
Outcome
IncreaseTrabecular thickness
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Micro-CT findings supported these outcomes, indicating significant improvements in bone volume, trabecular thickness, and structural integrity.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949506
07AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In rats with critical-size calvarial defects, graft combinations containing liraglutide showed improved structural integrity on micro-CT.
In plain wordsIn rats with skull bone defects, graft combinations containing liraglutide showed improved bone structure.
Peptide
Liraglutide
Outcome
IncreaseBone structural integrity
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Micro-CT findings supported these outcomes, indicating significant improvements in bone volume, trabecular thickness, and structural integrity.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949507
08AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
Among experimental groups of rats with critical-size calvarial defects, the liraglutide-autogenous graft group had the highest new bone formation.
In plain wordsIn rats with skull bone defects, the liraglutide-autogenous graft group had the highest observed new bone formation.
Peptide
Liraglutide
Outcome
IncreaseNew bone formation
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The Liraglutide-Autogenous graft group showed the highest levels of new bone formation and defect closure.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949508
09AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
Among experimental groups of rats with critical-size calvarial defects, the liraglutide-autogenous graft group had the highest defect closure.
In plain wordsIn rats with skull bone defects, the liraglutide-autogenous graft group had the highest observed defect closure.
Peptide
Liraglutide
Outcome
IncreaseDefect closure
Study
ratsn: not reported in source
critical-size calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The Liraglutide-Autogenous graft group showed the highest levels of new bone formation and defect closure.
2 context sentences(design, population, supporting numbers)
Summary · context
Critical-sized calvarial defects with a 5 mm diameter were created bilaterally in rats, and eight experimental groups were formed: Control, autogenous graft, allograft, xenograft, and the combination of each graft material with Liraglutide.
Summary · context
Bone healing was evaluated through histomorphometric analyses and micro-computed tomography (micro-CT).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4157949509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.